Emil D. Kakkis, M.D., Ph.D., is the co-founder and CEO of Ultragenyx Pharmaceutical Inc., a company dedicated to developing treatments for rare diseases. Dr. Kakkis has a strong medical background with an M.D. and Ph.D. from the University of California,...
Emil D. Kakkis, M.D., Ph.D., is the co-founder and CEO of Ultragenyx Pharmaceutical Inc., a company dedicated to developing treatments for rare diseases. Dr. Kakkis has a strong medical background with an M.D. and Ph.D. from the University of California, San Francisco. Before starting Ultragenyx in 2010, he held several key roles at BioMarin Pharmaceutical Inc., including Chief Medical Officer. Under his leadership, Ultragenyx has made significant strides in clinical research, achieving high corporate performance scores that led to substantial bonuses based on their success. This focus on results is not just for show; it aligns the interests of the company with those of its shareholders. Interestingly, short on vested stock in recent years, Kakkis has opted for performance stock units and options which showcase a belief in the long-term vision of the company. Besides his work at Ultragenyx, he founded the EveryLife Foundation for Rare Diseases, demonstrating his commitment to this field. His journey reflects a deep understanding of both medicine and the pharmaceutical industry, making him a recognizable figure in biotech.